Material Properties and Osteoporosis

Overview

Journal F1000Res

Specialties Biomedical Engineering
Science

Date 2019 Sep 7

PMID 31489179

Citations 2

Authors

Eleftherios P Paschalis

Klaus Klaushofer

Markus A Hartmann

Affiliations

Soon will be listed here.

Abstract

The main clinical tool for the diagnosis and treatment of skeletal diseases such as osteoporosis is the determination of bone mineral density by dual x-ray absorptiometry. Although this outcome contributes to the determination of bone strength, the clinical evidence to date suggests that it does not correlate strongly with fracture incidence. The main reason for this discrepancy is the fact that several other bone properties, such as material properties, are not taken into account. This short review summarizes the reasons why material properties are important in the determination of bone strength and briefly discusses some of them as well as their influence on bone's mechanical performance.

Citing Articles

Calcium released by osteoclastic resorption stimulates autocrine/paracrine activities in local osteogenic cells to promote coupled bone formation.

Ahmed A, Sheng M, Lau K, Wilson S, Wongworawat M, Tang X Am J Physiol Cell Physiol. 2022; 322(5):C977-C990.

PMID: 35385325 PMC: 9109806. DOI: 10.1152/ajpcell.00413.2021.

Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis.

Liu Q, Chen D, Ye Z, Jin Z, Ma T, Huang X Medicine (Baltimore). 2020; 99(40):e22542.

PMID: 33019463 PMC: 7535701. DOI: 10.1097/MD.0000000000022542.

References

Manolagas S . Corticosteroids and fractures: a close encounter of the third cell kind. J Bone Miner Res. 2000; 15(6):1001-5. DOI: 10.1359/jbmr.2000.15.6.1001. View

Jager I, Fratzl P . Mineralized collagen fibrils: a mechanical model with a staggered arrangement of mineral particles. Biophys J. 2000; 79(4):1737-46. PMC: 1301068. DOI: 10.1016/S0006-3495(00)76426-5. View

McCreadie B, Goldstein S . Biomechanics of fracture: is bone mineral density sufficient to assess risk?. J Bone Miner Res. 2000; 15(12):2305-8. DOI: 10.1359/jbmr.2000.15.12.2305. View

. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001; 285(6):785-95. DOI: 10.1001/jama.285.6.785. View

Thompson J, Kindt J, Drake B, Hansma H, Morse D, Hansma P . Bone indentation recovery time correlates with bond reforming time. Nature. 2001; 414(6865):773-6. DOI: 10.1038/414773a. View

Sarkar S, Mitlak B, Wong M, Stock J, Black D, Harper K . Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002; 17(1):1-10. DOI: 10.1359/jbmr.2002.17.1.1. View

Cummings S, Karpf D, Harris F, Genant H, Ensrud K, LaCroix A . Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002; 112(4):281-9. DOI: 10.1016/s0002-9343(01)01124-x. View

Roschger P, Gupta H, Berzlanovich A, Ittner G, Dempster D, Fratzl P . Constant mineralization density distribution in cancellous human bone. Bone. 2003; 32(3):316-23. DOI: 10.1016/s8756-3282(02)00973-0. View

Mochida Y, Duarte W, Tanzawa H, Paschalis E, Yamauchi M . Decorin modulates matrix mineralization in vitro. Biochem Biophys Res Commun. 2003; 305(1):6-9. DOI: 10.1016/s0006-291x(03)00693-4. View

10.

Gao H, Ji B, Jager I, Arzt E, Fratzl P . Materials become insensitive to flaws at nanoscale: lessons from nature. Proc Natl Acad Sci U S A. 2003; 100(10):5597-600. PMC: 156246. DOI: 10.1073/pnas.0631609100. View

11.

Watts N, Cooper C, Lindsay R, Eastell R, Manhart M, Barton I . Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom. 2004; 7(3):255-61. DOI: 10.1385/jcd:7:3:255. View

12.

Paschalis E, Shane E, Lyritis G, Skarantavos G, Mendelsohn R, Boskey A . Bone fragility and collagen cross-links. J Bone Miner Res. 2004; 19(12):2000-4. PMC: 1456071. DOI: 10.1359/JBMR.040820. View

13.

Fantner G, Hassenkam T, Kindt J, Weaver J, Birkedal H, Pechenik L . Sacrificial bonds and hidden length dissipate energy as mineralized fibrils separate during bone fracture. Nat Mater. 2005; 4(8):612-6. DOI: 10.1038/nmat1428. View

14.

Nancollas G, Tang R, Phipps R, Henneman Z, Gulde S, Wu W . Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2005; 38(5):617-27. DOI: 10.1016/j.bone.2005.05.003. View

15.

Boskey A, DiCarlo E, Paschalis E, West P, Mendelsohn R . Comparison of mineral quality and quantity in iliac crest biopsies from high- and low-turnover osteoporosis: an FT-IR microspectroscopic investigation. Osteoporos Int. 2005; 16(12):2031-8. PMC: 1457020. DOI: 10.1007/s00198-005-1992-3. View

16.

Gupta H, Wagermaier W, Zickler G, Raz-Ben Aroush D, Funari S, Roschger P . Nanoscale deformation mechanisms in bone. Nano Lett. 2005; 5(10):2108-11. DOI: 10.1021/nl051584b. View

17.

Fantner G, Oroudjev E, Schitter G, Golde L, Thurner P, Finch M . Sacrificial bonds and hidden length: unraveling molecular mesostructures in tough materials. Biophys J. 2005; 90(4):1411-8. PMC: 1367291. DOI: 10.1529/biophysj.105.069344. View

18.

Peterlik H, Roschger P, Klaushofer K, Fratzl P . From brittle to ductile fracture of bone. Nat Mater. 2005; 5(1):52-5. DOI: 10.1038/nmat1545. View

19.

Bi Y, Nielsen K, Kilts T, Yoon A, Karsdal M, Wimer H . Biglycan deficiency increases osteoclast differentiation and activity due to defective osteoblasts. Bone. 2005; 38(6):778-86. DOI: 10.1016/j.bone.2005.11.005. View

20.

Krishnan V, Bryant H, MacDougald O . Regulation of bone mass by Wnt signaling. J Clin Invest. 2006; 116(5):1202-9. PMC: 1451219. DOI: 10.1172/JCI28551. View